Search

Displaying results 3291 - 3300 of 5506 in total
  1. Drug

    Benzylfentanyl

    go.drugbank.com/drugs/DB09182
    ExperimentalIllicit

    In 2010 it was removed from the list after it was found to have minimal opioid activity. … Benzylfentanyl has a Ki of 213nM at the mu opioid receptor, binding around 200x less strongly than fentanyl itself.

  2. Drug

    Tyloxapol

    go.drugbank.com/drugs/DB06439
    ApprovedInvestigational

    Tyloxapol is a non-ionic detergent often used as a surfactant.

  3. Drug

    Butropium

    go.drugbank.com/drugs/DB15968
    Experimental

  4. Drug

    Pegzilarginase

    go.drugbank.com/drugs/DB14780
    Approved

    Pegzilarginase is a recombinant, cobalt-substituted, and pegylated human arginase 1 enzyme therapy designed to address the underlying metabolic deficit in arginase 1 deficiency (ARG1-D). By substituting the native manganese cofactor with...

  5. Drug

    Resveratrol

    go.drugbank.com/drugs/DB02709
    Investigational

    It is a stilbenoid, a derivate of stilbene, and is produced in plants with the help of the enzyme stilbene synthase. It exists as cis-(Z) and trans-(E) isomers. … It has been claimed that it is readily degraded by exposure to light, heat, and oxygen.

    Synonyms: (E)-resveratrol, (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol
  6. Drug

    ADX-10061

    go.drugbank.com/drugs/DB05419
    Experimental

    It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.

  7. Drug

    Forasartan

    go.drugbank.com/drugs/DB01342
    Experimental

    Forasartan competes with angiotensin II for binding at the AT1 receptor subtype.

  8. Drug

    Aranidipine

    go.drugbank.com/drugs/DB09229
    Experimental

    [A31895] It was developed by Maruko Seiyaku, introduced by Taiho and launched in Japan in 1997.[T88] … It is a calcium antagonist with the formula methyl 2-oxopropyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate.

  9. Drug

    Faropenem medoxomil

    go.drugbank.com/drugs/DB05659
    Investigational

    It is being developed jointly by Replidyne, Inc. and Forest Laboratories, Inc.

  10. Drug

    Odevixibat

    go.drugbank.com/drugs/DB16261
    ApprovedInvestigational

    Odevixibat, or A4250, is an ileal sodium/bile acid cotransporter inhibitor indicated for the treatment of pruritus in patients older than 3 months, with progressive familial intrahepatic cholestasis (PFIC). Odevixibat is the first approv...